These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14704665)

  • 1. Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation.
    Plensa E; Gallardo E; Ribera JM; Batlle M; Oriol A; Costa J
    Bone Marrow Transplant; 2004 Jan; 33(1):119-20. PubMed ID: 14704665
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation.
    Cuzzola M; Irrera G; Iacopino O; Cuzzocrea A; Messina G; Console G; Iacopino P; Morabito F
    Clin Infect Dis; 2003 Oct; 37(7):e102-6. PubMed ID: 13130419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythema nodosum secondary to granulocyte colony-stimulating factor in a patient with Hodgkin lymphoma during CD34+ cell mobilization for autologous peripheral blood stem cell transplantation: a dose-mediated effect.
    George S; George B; Gorak E
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):816-7. PubMed ID: 16182183
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of hepatic graft-versus-host disease complicating autologous stem cell transplantation for relapsed Hodgkin's disease.
    Cutting R; Wright J; Underwood J
    Bone Marrow Transplant; 2006 Jul; 38(1):77-8. PubMed ID: 16715105
    [No Abstract]   [Full Text] [Related]  

  • 5. Application of pulsed-field gel electrophoresis to identify the source of bacterial contamination of peripheral blood progenitor cell products.
    Reich-Slotky R; Wu F; Della-Latta P; Savage DG; Schwartz J
    Transfusion; 2008 Nov; 48(11):2409-13. PubMed ID: 18657076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma.
    Arango JI; Restrepo A; Schneider DL; Callander NS; Ochoa-Bayona JL; Restrepo MI; Bradshaw P; Patterson J; Freytes CO
    Bone Marrow Transplant; 2006 Mar; 37(5):517-21. PubMed ID: 16435018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible coma secondary to cefepime neurotoxicity.
    Abanades S; Nolla J; Rodríguez-Campello A; Pedro C; Valls A; Farré M
    Ann Pharmacother; 2004 Apr; 38(4):606-8. PubMed ID: 14982986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function.
    Maganti R; Jolin D; Rishi D; Biswas A
    Epilepsy Behav; 2006 Feb; 8(1):312-4. PubMed ID: 16278098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
    Van Besien K; Mehra R; Wadehra N; Stock W; Khouri I; Giralt S; Devine S; Wickrema A; Peace D; Sosman J; Gajewski J; Champlin R
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):386-94. PubMed ID: 15148492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom burden in patients undergoing autologous stem-cell transplantation.
    Anderson KO; Giralt SA; Mendoza TR; Brown JO; Neumann JL; Mobley GM; Wang XS; Cleeland CS
    Bone Marrow Transplant; 2007 Jun; 39(12):759-66. PubMed ID: 17438588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
    Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S
    Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of post-transplant spironolactone on daily potassium requirements in patients undergoing autologous stem cell transplantation.
    Demirer T; Ayli M; Dagli M; Fen T; Haznedar R; Ustael N; Ustun T; Oymak A; Ozdel O; Muftuoglu O
    Bone Marrow Transplant; 2002 Nov; 30(10):703-4. PubMed ID: 12420210
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis.
    González-Vicent M; Díaz MA; Colmenero I; Sevilla J; Madero L
    Transpl Infect Dis; 2008 Jun; 10(3):193-6. PubMed ID: 18069930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens.
    Nosari A; Cairoli R; Ciapanna D; Gargantini L; Intropido L; Baraté C; Scarpati B; Santoleri L; Nador G; Pezzetti L; Morra E
    Bone Marrow Transplant; 2006 Sep; 38(6):413-6. PubMed ID: 16878144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
    Ballova V; Ladicka M; Vranovsky A; Lakota J
    Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected immune complications in patients with non-Hodgkin's lymphoma receiving CD34-selected autologous peripheral stem cell transplantation.
    Cordoba R; Arranz R; Cannata J
    Bone Marrow Transplant; 2005 Jun; 35(12):1217-8. PubMed ID: 15852026
    [No Abstract]   [Full Text] [Related]  

  • 18. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Tey S; Butler J; Durrant S; Hill G; Morton J; Kennedy G
    Bone Marrow Transplant; 2005 Sep; 36(6):553-4; author reply 554. PubMed ID: 16044146
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.